Gene therapy has revolutionised treatment for people living with sickle cell disease, a painful and debilitating condition affecting millions worldwide. According to a recent inquiry, new treatments have successfully treated the condition, but access remains limited due to high costs. Dr Natasha Archer, director of the Sickle Cell Program at the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, US, notes that while significant progress has been made, the therapy is still out of reach for many patients.
The condition disproportionately affects sub-Saharan Africa, which accounts for almost 80% of global cases. Basic care remains a significant challenge in many areas, highlighting the need for accessible and affordable treatments. Dr Alexis Thompson, paediatric haematologist at the Children's Hospital of Philadelphia and a professor of paediatrics at the University of Pennsylvania, US, stresses the importance of finding ways to make gene therapy more accessible.
Researchers and experts are exploring various options to increase access to gene therapy, including collaborations between healthcare organisations, governments, and industry partners. Dr Leon Tshilolo, professor of paediatrics and haematology at the University of Mbuji-Mayi, DR Congo, highlights the need for a comprehensive approach that addresses the social and economic challenges faced by patients and families. Professor Baba Inusa, consultant paediatrician in the School of Life Course & Population Sciences at King's College London, UK, adds that education and awareness campaigns can play a crucial role in promoting access to care.
The inquiry's findings demonstrate the complex interplay between medical, economic, and social factors affecting access to gene therapy. While significant challenges remain, the conversation around potential solutions offers hope for patients and families affected by sickle cell disease.
As the medical community continues to explore ways to increase access to gene therapy, experts stress the importance of collaboration and a comprehensive approach. With millions of people worldwide relying on early diagnosis and preventative medicines, the need for affordable and accessible treatments has never been more pressing.